Pharmaceutical interventions for emotionalism after stroke

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 3, 2019, Pages

  Allida, Sabine ^a   Patel, Kulsum ^b   House, Allan ^c   Hackett, Maree L ^d  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO; PSYCHOTROPIC AGENT;

CENTER FOR NEUROLOGIC STUDY-LABILITY SCALE; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; DRUG FATALITY; EMOTIONAL DISORDER; EMOTIONALISM; EVIDENCE BASED MEDICINE; HUMAN; META ANALYSIS; MORTALITY; PARALLEL DESIGN; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUASI EXPERIMENTAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; CRYING; LAUGHTER; PSYCHOLOGY;

AFFECTIVE SYMPTOMS; ANTIDEPRESSIVE AGENTS; CRYING; HUMANS; LAUGHTER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 85063617331     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003690.pub4     Document Type: Review

References (105)

1. Andersen G, Riis JO,. Citalopram for post-stroke pathological crying. Lancet 1993; 342 (8875): 837-9. 3306861
2. Andersen G, Vestergaard K, Riis JO,. Citalopram for post-stroke pathological crying. Journal of Neurology 1994; 241 Suppl 1: S81. 3306862
3. Andersen G, Vestergaard K, Riis JO,. Pathological crying and emotional lability-a controlled study of citalopram-a SSRI. Canadian Journal of Neurological Sciences 1993; 20 Suppl 4: S115. 3306863
4. Andersen G, Vestergaard K, Riis JO,. Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica 1994; 89: 151. 3306864
5. Flicker C, Anderson G,. Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society 1998; 46 (9): S67. 3306865
6. Brown KW, Sloan RL, Pentland B,. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica 1998; 98 (6): 455-8. 3306867
7. Burns A, Russell E, Stratton-Powell H,. A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. American Journal of Psychiatry. Toronto, Ontario, Canada, 1998: 1. 3306870
8. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R,. Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry 1999; 14 (8): 681-5. 3306869
9. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS,. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases 2008; 26 (3): 266-71. [PUBMED: 18648199] 3306872
10. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS,. Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease 2007; 23 (2-3): 103-8. 3306873
11. Choi-Kwon S, Choi JM, Kwon DW, Kim JS,. Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke 2008; 3 (Suppl 1): 405-6. 3306874
12. Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS,. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 2006; 37 (1): 156-61. [PUBMED: 16306470] 3306875
13. Choi-Kwon S, Kwon SU, Kang DW, Kim JS,. Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke 2009; 40 (4): e282. 3306876
14. Murray V, Von Arbin M, Asberg M, Bartfai A, Berggren A, Landtblom A, et al., Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Unpublished 2003. 3306878
15. Murray V, Von Arbin M, Varelius R, Olsson JE, Terent A, Samuelsson M, et al., Sertraline in poststroke depression: a controlled study. Stroke 2002; 33 (1): 292. 3306879
16. Murray V, von Arbin M, Bartfai A, Berggren AL, Landtblom AM, Lundmark J, et al., Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry 2005; 66 (6): 708-16. [PUBMED: 15960563] 3306880
17. Ohkawa S, Mori E, Yamadori A,. Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku [Clinical Neurology] 1989; 29 (9): 1183-5. 3306882
18. Parikh RM, Robinson RG, Lipsey JR, Price TR,. Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology 1989; 39 Suppl 1: 177. 10251756
19. Robinson R,. Additional data provided by author. Unpublished 2003. 10251757
20. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR,. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry 1993; 150 (2): 286-93. 10251758
21. Aizawa T, Kase M, Kutsuzawa T, Hasegawa T, Sekimoto H, Omae T,. Clinical evaluation on the effect of cyclandelate in the treatment of cerebrovascular diseases: double-blind comparative placebo-controlled clinical study with cinnarizine as a basic treatment. Rinsho Hyoka [Clinical Evaluation] 1977; 5 (3): 659-86. 3306888
22. Allen C, Zarowitz B, O'Shea T, Peterson E, Yonan C, Waterman F,. Identification of pseudobulbar affect symptoms in the nursing home setting: development and assessment of a screening tool. Geriatric Nursing 2018; 39 (1): 54-9. 10251760
23. Atarashi J, Ohtomo E, Kogure K, Hirai S, Tazaki Y, Araki G, et al., Clinical utility of HYG-FAS in treatment of cerebrovascular disorders: multi-center double-blind study in comparison with hydergine tablet 2mg. Rinsho Hyoka [Clinical Evaluation] 1988; 16 (3): 425-86. 3306890
24. Bassi S, Albizzati MG, Sbacchi M, Frattola L,. Chronic cerebrovascular disorders: clinical study with cyclandelate. British Journal of Clinical Practice 1984; 38: 344-9. 3306892
25. Chen YR, Huang YP, Lin SJ, Kuan TH, Lin CH,. Effectiveness of quetiapine for poststroke pathological laughing: case report and review of literature. Clinical Neuropharmacology 2010; 33 (6): 319-22. 10251762
26. Colamonico J, Formella A, Bradley W,. Psuedobulbar affect: burden of illness in the USA. Advances in Therapy 2012; 29 (9): 775-98. 10251764
27. D'Amico S, Alexander DN, Cutler AJ, Zorowitz RD, Davis CS, Shin P, et al., Safety and tolerability of dextromethorphan/quinidine in older patients. American Journal of Geriatric Psychiatry 2017; 25 (3 Suppl 1): S142. 10251766
28. Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al., Safety, tolerability and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer's Disease/Dementia: PRISM-II. Annals of Neurology 2014; 76 (Suppl 18): S99-S100. 10251768
29. Formella AE, Alexander DN, Cutler AJ, D'Amico S, Hammond FM, Sauve W, et al., Dextromethorpha/quinidine improved symptoms of pseudobulbar affect irrespective of concomitant antidepressant use. CNS Spectrums 2017; 22 (1): 64-5. 10251770
30. Formella AE, Alexander DN, Cutler AJ, D'Amico S, Hammond FM, Sauve W, et al., Dextromethorphan/quinidine improved symptoms of pseudobulbar affect irrespective of concomitant antidepressant use. Neurology 2017; 88 (Suppl 1): 1-2. 10251772
31. Kim JS, Lee EJ, Chang DI, Park JH, Ahn SH, Cha JK, et al., The efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry 2017; 4 (1): 33-41. 10251774
32. NCT01278498,. The Preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. Clinicaltrials.gov/ct2/show/NCT01278498 (date first received 19 January 2011). 10251775
33. Kim JS,. Management of post-stroke mood and emotional disturbances. Expert Review of Neurotherapeutics 2017; 17 (12): 1179-88. 10251777
34. Lawson IR, MacLeod RD,. The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry 1969; 115 (520): 281-5. 3306894
35. Manzo JF, Health RL, Blonder LX,. The interpersonal management of crying among survivors of stroke. Sociological Spectrum 1998; 18 (2): 161-84. 10251779
36. Moller M, Andersen G, Gjedde A,. Serotonin 5HT1A receptor availability and pathological crying after stroke. Acta Neurologica Scandinavica 2007; 116 (2): 83-90. 3306896
37. Muller U, Murai T, Bauer-Wittmund T, Cramon DY,. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury 1999; 13 (10): 805-11. 3306898
38. Narushima P, Kosier J, Robinson R,. Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. Journal of Nervous and Mental Disease 2002; 190 (5): 296-303. 3306900
39. Ohtomo E, Kutsuzawa T, Araki G, Hirai S, Terashi A, Kuzuya F, et al., Clinical usefulness of tiapride on psychiatric symptoms caused by cerebrovascular disorders: a multi-center double-blind study in comparison with inactive placebo. Rinsho Hyoka [Clinical Evaluation] 1985; 13 (2): 295-332. 3306902
40. Otomo E, Saso S, Araki G, Hirai S, Atarashi J, Hasegawa K, et al., Clinical evaluation of amantadine hydrochloride (Symmetrel) in the treatment of cerebrovascular disorders with psychiatric symptoms: multi-center double-blind study in comparison with placebo. Rinsho Hyoka [Clinical Evaluation] 1984; 12 (2): 321-67. 3306904
41. Rasmussen A,. A double blind controlled study of the influence of sertraline on the incidence of post stroke depression and on emotional lability [PhD Thesis]. Copenhagen (Denmark): University of Copenhagen, 2000. 3306907
42. Rasmussen A,. A double-blind, placebo-controlled study of the prophylactic effect of sertraline in post stroke emotional lability. European Neuropsychopharmacology. Germany: Elsevier, 2000. 3306908
43. Rasmussen A,. A double-blind, placebo-controlled study of the prophylactic effect of sertraline in post stroke emotional lability. Nordic Psychiatric Congress. Copenhagen, 25 August, 2000. 3306909
44. Rasmussen A,. Post-stroke emotional lability: a double-blind psychopharmacological treatment with sertraline. Nordic Journal of Psychiatry 2000; 54: 35. 3306910
45. Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P,. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003; 44 (3): 216-21. 3306906
46. Sauve W, Alexander DN, Cutler AJ, D'Amico S, Hammond FM, Zorowitz RD, et al., Neurological and psychiatric comorbidities assessment in the PRISM II study of dextromethorphan/quinidine for treatment of pseudobulbar affect. CNS Spectrums 2017; 22 (1): 104. 10251781
47. Schiffer RB, Herndon RM, Rudick RA,. Treatment of pathologic laughing and weeping with amitriptyline. New England Journal of Medicine 1985; 312 (23): 1480-2. 3306912
48. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K,. Fluoxetine improves emotional incontinence. Brain Injury 1992; 6 (3): 267-70. 3306914
49. Udaka F, Yamao S, Nagata H, Nakamura S, Kameyama M,. Pathologic laughing and crying treated with levodopa. Archives of Neurology 1984; 41 (10): 1095-6. 3306916
50. Work SS, Colamonico JA, Bradley WG, Kaye RE,. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Advances in Therapy 2011; 28 (7): 586-601. 10251783
51. Yang LPH, Deeks ED,. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Drugs 2015; 75 (1): 83-90. 10251785
52. Allman P,. Crying and laughing after brain damage: a confused nomenclature. Journal of Neurology, Neurosurgery, and Psychiatry 1989; 52 (12): 1439-40
53. Allman P,. Drug treatment of emotionalism following brain damage. Journal of the Royal Society of Medicine 1992; 85 (7): 423-4
54. Allman P, Marshall M, Hope A, Fairburn C,. Emotionalism following stroke: development and reliability of a semi-structured interview. International Journal of Methods in Psychiatric Research 1992; 2: 125-31
55. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IIIR. Washington, DC: American Psychiatric Association, 1987
56. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association, 1994
57. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington VA: American Psychiatric Publishing, 2017
58. Atkins D, Best D, Briss PA, Eccles M, Falck-Yitter Y, Flottorp G, et al., GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328 (7454): 1490
59. Beck AT, Ward C, Mendelson M,. An inventory for measuring depression. Archives of General Psychiatry 1961; 4: 561-71
60. Benedek D, Peterson KA,. Sertraline for treatment of pathological crying. American Journal of Psychiatry 1995; 152 (6): 953-4
61. Brookshire R,. Control of "involuntary" crying behaviour emitted by a multiple sclerosis patient. Journal of Communication Disorders 1970; 3 (3): 171-6
62. Calvert T, Knapp P, House A,. Psychological associations with emotionalism after stroke. Journal of Neurology, Neurosurgery and Psychiatry 1998; 65 (6): 928-9
63. Deeks JJ, Higgins JP, Altman DG, editors. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration
64. Folstein MF, Folstein SE, McHugh PR,. 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975; 12 (3): 189-98
65. Gillespie D, Cadden AP, Lees R, West RM, Broomfield NM,. Prevalence of psuedobulbar affect following stroke: A systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases 2016; 25 (3): 688-94
66. Goldberg DP,. The Detection of Psychiatric Illness by Questionnaire. Vol. 21, Oxford: Oxford University Press, 1972
67. Gompertz P, Pound P, Ebrahim S,. The reliability of stroke outcome measurement. Clinical Rehabilitation 1993; 7 (4): 290-6
68. McMaster University (developed by Evidence Prime). GRADEproGDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015
69. Hamilton M,. Rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23: 56-62
70. Hanger HC,. Emotionalism after stroke. Lancet 1993; 342 (8881): 1235-6
71. Higgins JP, Green S, editor(s),. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. John Wiley & Sons
72. House A, Dennis M, Molyneux A, Warlow C, Hawton K,. Emotionalism after stroke. BMJ 1989; 298 (6679): 991-4
73. Hunt SM, McEwen J, McKenna SP,. Measuring Health Status. Beckenham: Croom Helm, 1986
74. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992
75. Kim JS, Choi-Kwon S,. Post stroke depression and emotional incontinence. Neurology 2000; 54 (9): 1805-10
76. Kim SW, Shin IS, Kim JM, Lim SY, Yang SJ, Yoon JS,. Mirtazapine treatment for pathological laughing and crying after stroke. Clinical Neuropharmacology 2005; 28 (5): 249-51
77. Lauterbach E, Schweri M,. Amelioration of pseudobulbar affect by fluoxetine. Journal of Clinical Psychopharmacology 1991; 11: 392-3
78. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009; 6 (7): e1000100
79. Mahoney FI, Barthel DW,. Functional evaluation: the Barthel Index. Maryland State Medical Journal 1965; 14: 61-5
80. Massey E, Lowe S,. Lithium carbonate in pseudobulbar palsy. Annals of Neurology 1981; 9 (1): 97
81. Montgomery SA, Asberg M,. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979; 134: 382-9
82. Moore S, Gresham L, Bromberg M, Kasarkis E, Smith R,. A self-report measure of emotional lability. Journal of Neurology, Neurosurgery and Psychiatry 1997; 63 (1): 89-93
83. Mukand J, Kaplan M, Senno RG, Bishop DS,. Pathological crying and laughing: treatment with sertraline. Archives of Physical Medicine and Rehabilitation 1996; 77 (12): 1309-11
84. Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS,. Rapid response of emotional incontinence to selective serotonin reuptake inhibitor. Journal of Neuropsychiatry and Clinical Neurosciences 1998; 10: 453-5
85. Newsom-Davis I, Abraham S, Goldstein L, Leigh P,. The emotional lability questionnaire: a measure of emotional lability in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1999; 169 (1-2): 22-5
86. Panzer MJ, Mellow AM,. Antidepressant treatment of pathological laughing or crying in elderly stroke patients. Journal of Geriatric Psychiatry and Neurology 1992; 5 (4): 195-9
87. Poeck K,. Pathophysiology of emotional disorders associated with brain damage. In:, Vinken PJ, Bruyn GW, editor(s). Handbook of Clinical Neurology. Holland: Holland Publishing Co, 1969: 343-67
88. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014
89. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR,. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry 1993; 150 (2): 286-93
90. Sacco S, Sarà M, Pistoia F, Conson M, Albertini G, Carolei A,. Management of pathologic laughter and crying in patients with locked-in syndrome: a report of 4 cases. Archives Physical Medicine and Rehabilitation 2008; 89 (4): 775-8
91. Sandyk R, Gillman MA,. Nomifensine for emotional incontinence in the elderly. Clinical Neuropharmacology 1985; 8 (4): 377-8
92. Schiffer R, Cash J, Herndon R,. Treatment of emotional lability with low dosage tricyclic antidepressants. Psychosomatics 1983; 24: 1094-6
93. Schunemann HJ, Oxman AD, Higgins JP, Vist GE, Glazziou P, Guyatt GH,. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration
94. Seliger GM, Hornstein A,. Serotonin, fluoxetine, and pseudobulbar affect. Neurology 1989; 39 (10): 1400
95. Sloan RL, Brown KW, Pentland B,. Fluoxetine as a treatment for emotional lability after brain injury. Brain Injury 1992; 6 (4): 315-9
96. Smith AG, Montealegre-Orjuela M, Douglas JE, Jenkis EA,. Venlafaxine for pathological crying after stroke. Journal of Clinical Psychiatry 2003; 64 (6): 731-2
97. Tan I, Dorevitch M,. Emotional incontinence: a dramatic response to paroxetine. Australian and New Zealand Journal of Medicine 1996; 26 (6): 844
98. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J,. Inter-observer agreement for the assessment of handicap in stroke patients. Stroke 1998; 19 (5): 604-7
99. Walker MF, Hoffmann TC, Brady MC, Dean CM, Eng JJ, Farrin AJ, et al., Improving the development, monitoring and reporting of stroke rehabilitation research: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabilitation and Neural Repair 2017; 31 (10-11): 877-84
100. Ware JE, Snow KK, Kosinski M, Gandek B,. SF-36 Health Survey: Manual and Interpretation Guide. Boston (MA): New England Medical Center, Health Institute, 1993
101. Wolf J, Santana H, Thorpy M,. Treatment of 'emotional incontinence' with levodopa. Neurology 1997; 29: 1935-6
102. Zigmond AS, Snaith RP,. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandanavica 1983; 67 (6): 361-70
103. Hackett ML, Yang M, Anderson CS, Horrocks JA, House A,. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD003690.pub3 ]
104. House AO, Anderson CS, Hackett ML, Horrocks JA,. Interventions for emotionalism after stroke [Protocol]. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD003690 ]
105. House AO, Hackett ML, Anderson CS, Horrocks JA,. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD003690 ]